While one company will focus on drug discovery, the other, which will retain the company name, will have Tysabri (co-marketed with Biogen Idec Inc. ( BIIB )), ELND005 (phase II) and Elan's interest in Johnson & Johnson 's ( JNJ ) Janssen Alzheimer Immunotherapy. The company which will focus on drug discovery will be named Neotope Biosciences. The company, which will function under the name Elan Corporation, is expected to be profitable, generating significant growth, immediately following the spin-off. This company is expected to generate earnings of $1.00 per share by 2015 and will focus on broadening Tysabri's reach, apart from facilitating ELND005's development. Elan Corporation, apart from providing the initial capital of $120-$130 million to Neotope Biosciences, will retain a 14-18% minority equity interest in Neotope. Neotope Biosciences intends to file three investigational new drug ( IND ) applications by 2015.